Ravulizumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Ravulizumab
- Pharmacist Assessment Report
- Ravulizumab: Autosomal recessive severe congenital neutropenia due to G6PC3 deficiency
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Ravulizumab: Autosomal recessive severe congenital neutropenia due to G6PC3 deficiency
One-Sentence Summary
Ravulizumab is a long-acting C5 complement inhibitor, originally used to treat paroxysmal nocturnal haemoglobinuria (PNH). The TxGNN model predicts it may be effective for autosomal recessive severe congenital neutropenia due to G6PC3 deficiency, but there are currently no clinical trials and no publications supporting this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Autosomal recessive severe congenital neutropenia due to G6PC3 deficiency |
| TxGNN Prediction Score | 0.9996 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, ravulizumab is a long-acting inhibitor of complement component C5. It blocks terminal complement activation, which is the basis of its efficacy in PNH, a complement-mediated haemolytic disease.
For the predicted indication, no direct mechanistic link is established. G6PC3 deficiency causes neutropenia through impaired glucose metabolism and neutrophil apoptosis, and no role for complement C5 has been recognised. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. It is not supported by trials or literature.
Other top-ranked predictions show the same pattern. They include cyclic haematopoiesis, severe congenital neutropenia, CXCR2 deficiency, primary hyperoxaluria, pseudo-von Willebrand disease and megaloblastic anaemia. Each has a rationale that is weak or speculative. The only tentative link is in primary hyperoxaluria, where complement inhibition could theoretically reduce secondary renal inflammation. That remains hypothetical.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 12841W | Ultomiris | Solution concentrate for I.V. infusion, 300 mg in 3 mL | Not available in the data compiled for this report |
Safety Considerations
- Contraindications (knowledge graph, not label text): Meningococcal infection. Terminal complement inhibition is known to increase the risk of serious meningococcal disease.
- Drug Interactions: Four minor interactions were identified, all with human immunoglobulin G preparations (intravenous, subcutaneous, intramuscular, and intravenous and subcutaneous).
- Population concern: For primary immunodeficiency-type predictions (such as p14 deficiency), complement blockade could further increase infection risk in an already immunodeficient population.
Please refer to the TGA-approved Product Information (PI) for full warnings and precautions. Label-based warnings were not available in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting clinical trials or publications and no plausible mechanistic link between C5 inhibition and G6PC3-deficiency neutropenia. Complement inhibition also carries a serious meningococcal infection risk, which is hard to justify without any efficacy signal.
To proceed, the following is needed:
- A clear mechanistic rationale linking terminal complement activation to the predicted disease, supported by preclinical data
- Detailed mechanism of action data for ravulizumab
- Label-based warnings and contraindications from the TGA-approved Product Information, to complete safety screening
- The approved indication text for ARTG 12841W
- Any clinical or literature evidence, such as case reports or early-phase studies, in the predicted indication
- Reassessment of the lower-ranked predictions (for example, primary hyperoxaluria) only if new supporting evidence emerges
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.